Evidence map›Paper›PMID 35764050›Full record

ArticleOncology2022

Impact of Sites of Metastatic Dissemination on Survival in Advanced Gastroesophageal Adenocarcinoma.

Xin Wang, Osvaldo Espin-Garcia, Di Maria Jiang, Michael J Allen, Lucy X Ma, Yvonne Bach, Eric X Chen, Gail Darling, Johnathan C Yeung, Rebecca K S Wong and 4 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 2 countries.

Xin WangPrincess Margaret Cancer Centre, University Health Network, Toronto, Ontario, USA.
Osvaldo Espin-GarciaPrincess Margaret Cancer Centre, University Health Network, Toronto, Ontario, USA.
Di Maria JiangPrincess Margaret Cancer Centre, University Health Network, Toronto, Ontario, USA.
Michael J AllenPrincess Margaret Cancer Centre, University Health Network, Toronto, Ontario, USA.
Lucy X MaPrincess Margaret Cancer Centre, University Health Network, Toronto, Ontario, USA.
Yvonne BachPrincess Margaret Cancer Centre, University Health Network, Toronto, Ontario, USA.
Eric X ChenPrincess Margaret Cancer Centre, University Health Network, Toronto, Ontario, USA.
Gail DarlingPrincess Margaret Cancer Centre, University Health Network, Toronto, Ontario, USA.
Johnathan C YeungPrincess Margaret Cancer Centre, University Health Network, Toronto, Ontario, USA.
Rebecca K S WongPrincess Margaret Cancer Centre, University Health Network, Toronto, Ontario, USA.
Patrick Veit-HaibachPrincess Margaret Cancer Centre, University Health Network, Toronto, Ontario, USA.
Sangeetha KalimuthuPrincess Margaret Cancer Centre, University Health Network, Toronto, Ontario, USA.
Raymond W JangPrincess Margaret Cancer Centre, University Health Network, Toronto, Ontario, USA.
Elena ElimovaPrincess Margaret Cancer Centre, University Health Network, Toronto, Ontario, USA.
Princess Margaret Cancer Centre · CAUniversity Health Network · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionMetastatic gastroesophageal adenocarcinoma (GEA) is a heterogeneous disease with an overall poor prognosis. The impact of sites of metastatic dissemination on survival is not well characterized. This study aimed to evaluate whether certain sites of metastatic disease impacts survival.

methodsA retrospective analysis of 375 patients with metastatic GEA treated at the Princess Margaret Cancer Centre from 2006 to 2016 was performed. Overall survival (OS) and progression-free survival (PFS) were estimated using the Kaplan-Meier method. Cox proportional hazards regression models were used to assess the association between sites of metastases and OS adjusting for baseline patient characteristics.

resultsMedian duration of follow-up was 47.8 months. Median OS in this cohort was 11.8 months (95% CI: 10.2-12.9 months). Patients with lymph node only disease, compared to those with other sites of metastases, had the longest median OS (20.4 vs. 10.6 months; p < 0.001) and PFS (11.4 vs. 6.3 months; p < 0.001). On multivariable analysis adjusting for relevant clinical factors including age, sex, and Eastern Cooperative Oncology Group performance status, the presence of lung (HR 1.67, 95% CI: 1.23-2.26; p < 0.001) or bone metastases (HR 1.84, 95% CI: 1.31-2.59; p < 0.001) were independently associated with shorter OS. The majority of patients (68%) were treated with palliative intent first-line platinum-based chemotherapy. DISCUSSION/

conclusionPatients with metastatic GEA have an overall poor prognosis. The presence of lung or bone metastases is an independent risk factor for decreased survival. Prognostic models incorporating sites of metastasis should be considered in the clinical evaluation of metastatic GEA.

Indexed as

AdenocarcinomaBone NeoplasmsNeoplasms, Second PrimaryDisease-Free SurvivalHumansPrognosisProportional Hazards ModelsRetrospective StudiesEsophageal cancerGastric cancerMetastasisPrognostic factorsSurvival

Identifiers

PMID35764050
PMCPMC9533436
OpenAlexW4283699643

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.